Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Many New Oncology Drugs In 2012, With Prices That Test The Limits

Jan 28 2013

• By Jessica Merrill

Related Content

Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High

Jan 07 2013

Precision Medicine And The Advent Of The “Niche Buster”: An Interview With GSK’s Paolo Paoletti

Jan 21 2013

Questioning <em>Stivarga</em>’s Cost-Effectiveness In Colon Cancer

Dec 03 2012

Role Of Cost And Evidence In Value-Based Purchasing Highlighted By Zaltrap Price Adjustment

Dec 24 2012

The <em>Zaltrap</em> Price Debate: Less Than Meets The Eye

Nov 20 2012

FDA Approves <em>Zytiga</em> In Earlier Prostate Cancer Setting

Dec 11 2012

GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair

Jun 05 2012

Dendreon Set To Ship Provenge Within A Week

Apr 29 2010

Related Companies

Bayer AG

Onyx Pharmaceuticals, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc.

Dendreon Corporation

Memorial Sloan Kettering Cancer Center

Johnson & Johnson

Astellas Pharma, Inc.

Medivation, Inc.

Bristol Myers Squibb Company

GSK plc

Additional Topics

Pricing Strategies Launches BioPharmaceutical

More from Pricing Debate

More from Market Access

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window